1. Introduction
Fractures are the main characteristic in patients with osteogenesis imperfecta (OI), also called “brittle bone disease”. OI is a genetic disorder with a disturbance of the production and structure of collagen type I, one of the main components of bone tissue. This rare bone disease has an incidence of 1 in 15,000–20,000 births [
1]. The patients are generally clinically classified from type 1 to 5 [
2], in which type 1 has the mildest symptoms and type 3 represents the most severe type compatible with life. Type 4 has a severity between type 1 and 3, and type 2 is defined as perinatal lethal. Type 5 has distinctive radial head luxation’s and ossification of the interosseous membrane. In addition to the Sillence classification, several rare types have now been described in the literature [
3]. Eighty-five percent of the OI population has an autosomal dominant inheritance (types 1–5,15), of which the types 1–4 have a primary collagen type 1 defect. The remainder of 15% has an autosomal recessive inheritance, and the mutations in these patients affect the metabolic pathway of bone formation in different ways. A classification based on the metabolic pathway has been proposed by Forlino et al. in 2017 [
3]. The list of OI types has been increasing; these additional types are clinically more or less similar to OI type 3 in terms of severity. Clinical manifestations vary widely between the different types of OI, ranging from patients who have mild symptoms with few fractures and a normal life expectancy, to patients with frequent fractures and severe bony deformities together with severe physical impairments and reduced life expectancy [
4,
5,
6].
2. Collagen and Bone Tissue Formation
Bone tissue, or matrix, is made from collagen molecules and inorganic hydroxyapatite (HA) minerals. The structure of bone matrix can be compared with reinforced concrete, where the inorganic (HA) minerals are the cement, and the collagen molecules are the steel reinforcement. Biomechanically, the inorganic HA crystals give bone matrix its stiffness, and the reinforcement with collagen type 1 fibers creates the mechanical flexibility and related toughness. Bone tensile strength and resistance to both traction and shearing forces is mainly determined by the collagen network, making up around 30% of the bone matrix [
7,
8].
Collagen is made intracellularly and is a protein with a triple helix structure of peptide chains that are closely packed in a characteristic quarter-staggers array to form a fibril. A collagen fiber is made from multiple fibrils in the same way as multiple small iron threads together form a steel cable see
Figure 1 and
Figure 2 for more details on both normal collagen formation and collagen formation in OI [
9].
After the extrusion of collagen by the cell into the extracellular matrix, inorganic HA is deposited as crystals in and between the fibrils and fibers, resulting in increased stiffening to finally become mineralized bone matrix (see
Figure 2).
3. Bone Strength and Elasticity in OI
The OI bone matrix has a lower capacity for energy absorption due to a lower strength and elasticity (
Figure 3). The weaker bone matrix is susceptible to micro-damage, which causes increased activity of both osteoclasts and osteoblasts to repair these micro-damages. Increased osteoblast activity subsequently increases the osteocyte density, and thus leaves an increased porosity of bone due to osteocyte lacunae. Most likely, this increased activity at the cell level also causes an increased vascularity in the bone, which in turn adds on the increase in porosity. An increased pore percentage in OI bone has been reported at both the level of osteocyte lacunae and vascularity [
10]. Next to the lower biomechanical properties of the bone matrix itself, a small rise in bone pore percentage might lead to significantly increased crack propagation through bone, in particular with repetitive loading and the accumulation of micro-damaged sites. For example, a bone pore percentage increase from 4% to 20% results in a three-fold decrease in the deformation abilities of bone before fracture [
11], and thus much less energy uptake that refers to the bones brittleness (
Figure 3).
Bone strength is also decreased at the level of bone micro and macro architecture. The refinement of bone imaging technologies in recent years has especially improved the assessment of bone architecture. Measures of bone micro-architecture, bone geometry, and (volumetric) bone mass density (vBMD) can be obtained by high-resolution peripheral quantitative computed tomography (HR-pQCT) [
12]. A significantly decreased cortical thickness was found in tibiae of type 1 OI patients using HR-pQCT but normal to increased cortical thickness in OI types 3 and 4 [
13]. Both histomorphometric and HR-pQCT evaluation of cancellous iliac bone biopsies in patients with OI showed fewer and thinner trabeculae [
13,
14,
15] The Trabecular Bone Score (TBS) as measured with HR-pQCT is related to trabecular connectivity and trabecular spacing, and low TBS in peripheral bone has a strong association with individual fracture risk [
16]. In OI patients type 3 and type 4, lower TBS values were found compared to normal bone [
13]. All these pathologic changes at the different architectural levels also add to the susceptibility of fractures in patients with OI.
4. Fracture Management
Fracture management in OI patients need a very tailor-made approaches, but general principles apply to all OI patients. When OI patients suffer from a fracture, emergency treatment should preferably be provided at the nearest possible institution. While some fractures do not require any treatment, some fractures need immobilization with plaster of Paris (POP), and some fractures need surgery with reinforcing intramedullary implants. Patients and family education on OI can be very beneficial in pain management, transportation, and logistics in these emergencies. Some clinics teach patients and/or parents to apply a temporary plaster or splint themselves in order to cope with the first pain before adequate professional healthcare is available. When POP is utilized, we prefer the use of flexible material over a rigid cast. Since the bone in OI is brittle, the end of a rigid cast might create a stress riser, which increases the risk of additional fractures during treatment with a cast. This risk could be minimized with more flexible cast materials.
The average time to consolidation in OI patients is lower than in controls, due to a higher bone turnover in OI bone (higher vascularity and higher cellularity). Hence, a relatively short period of immobilization is often sufficient. When surgical treatment is indicated, the authors feel that pre-existing deformity of the bone should be repaired where possible to minimize the risk of re-fracture. The simultaneous correction of deformities on the contralateral side and adjacent bone should also be considered in order to minimize frequency of surgeries and periods of immobilization for all OI patients.
5. Prevention of Fractures
5.1. Medication
As for all children, maintaining adequate vitamin D (vit D) concentrations is one of the basic pre-requisites for normal bone mineralization and bone mass [
17]. Children with OI seem to be at risk for vit D deficiency, especially those with more severe OI and/or a high body mass index [
18]. Therefore, children with OI should have their vit D status monitored and be supplied with a dietary vitamin D supplement to ensure optimal levels [
9]. Bisphosphonate (BP) treatment is now widely employed in OI patients to improve bone mass. BP decreases bone resorption by osteoclasts, shifting the balance of bone resorption and bone formation towards more OI bone formation [
19]. Based on bone mineral density (BMD) and fracture rate, BP treatment might be started early. A low BMD is not the only factor causing lower bone strength in OI. The porosity, architecture, and connectivity within bone structure, as well as the quality of collagen fibers and the collagen to mineral ratio, play important roles in decreased bone strength. BP treatment can decrease pore percentage and increase BMD, but cannot change all factors involved in the decreased bone strength in OI.
Although the impact is not completely understood yet, BPs affect osteoblast and osteocyte activity directly. The main effect of BPs in the treatment of OI lies in the modulation of osteoclast activity, altering the structure and the architecture of bone [
9]. A decrease in bone turn-over is usually not a problem in children. Children with OI have a higher bone turn-over compared to children without OI. Since adults have a decrease in bone turn-over with increasing age, bisphosphonates should be used with caution in adult OI patients. Indications are stricter, and lower frequencies of BP admission is advised [
20] in order to keep turnover at a minimum level, which is a prerequisite to prevent the accumulation of micro-damage and related so-called ‘spontaneous’ fractures [
21].
Increased BMD is usually most prominent in the first year of treatment. The effect of BP is patient specific and should be monitored yearly with fracture frequency and BMD. Since BP therapy only modulates osteoclast activity, some researchers focus on new medication strategies, a phase 1 study on mesenchymal stem cell treatment [
22] in which they try to create a mosaic DNA is ongoing. A phase 2a clinical trial with antisclerostin [
23] together EMA and FDA approval opens the path to a phase 3 pediatric study with antisclerostin in OI. Antisclerostin increases osteoblast activity rather than decreasing osteoclast activity, as BP do. Results from this research might change the outcomes for patients with OI in the near future.
5.2. Physical Activity
Good motor skills and physical activity are important for proper bone development and the prevention of fractures in all people. During exercise, the effect of loading has positive influences on both the quantity and quality of bone [
24]. In OI, collagen type 1 affects not only the bone, but also the soft tissues in the musculoskeletal system. Increased laxity, quantified by using the Beighton score, is often found in these patients. Furthermore, muscle weakness is present more often. Muscle weakness might be directly related to the altered collagen type 1 formation [
25]. Keeping the patient physically active with tailor-made activity training programs is mandatory.
5.3. Preventive Surgery
Alignment surgery with intramedullary rodding to increase bone strength should be considered to decrease the fracture risk in children with moderate to severe OI. Teamwork and clear communication with the patient and family, surgeon, and multidisciplinary team are essential for a shared decision-making process. Pre-operatively, baseline function, range of motion, muscle strength and length, pain, and quality of life should be measured, preferably using standardized and validated outcome measures [
26], and re-assessed after fracture treatment. Elongating implants or constructs for stable longitudinal growth are usually preferred in growing children. The inserted intramedullary rods are left in the bones as long as possible to prevent re-fractures. However, the re-operation rate due to rod migration and telescoping failure is very high, and re-revision rates of 30% within 5 years of follow-up have been reported with the current elongating devices [
27]. Fixed-length devices can be used as an alternative when bone size is small, for children with limited residual growth or when lengthening devices are not available [
28]. Plates and screws as stand-alone implants should be avoided to prevent stress fractures at the edges of the plates (see
Figure 4) in all OI patients.
Postoperative immobilization is provided with a flexible backslab or plaster cast, followed by initiation of mobilization as soon as healing permits [
28].
General considerations and recommendations about surgical treatment in both fracture management and preventive surgery for both children and adults have recently been published after an international task force reached consensus in a standardized way [
28].
5.4. Rehabilitation
After fracture management or elective surgery, patients need a personalized rehabilitation program. An early start of rehabilitation after surgery is strongly advised. The rehabilitation program should preferably be done in the patient’s own environment. A multidisciplinary OI team should provide a rehabilitation program and stay connected to both patient and their local health care professionals during the rehabilitation. If the patient will wear a cast or have a partial on non-weightbearing regime, patients and their families need to learn safe methods for transfers and daily care before discharge from hospital. It is advisable to practice these transfers before surgery to become familiar with the available aids and prescribed methods. The rehabilitation program should focus on range of motion, muscle strength, and improvement of general functioning. Besides that, psychological support can be beneficial for some patients. Any rehabilitation progress should be evaluated in line with patient and family goals and surgeon’s protocol.
In addition to rehabilitation care following the acute phase of fractures or surgery, continuous guidance from a rehabilitation team is important to support children with OI in optimal development and participation in society (e.g., mobility, personal care, school, and sports). The international classification of functioning, disability, and health (ICF) can be used as a framework to cover all important domains. Recently, an international interdisciplinary working group called Key4OI developed a set of global outcome measures for patients with OI using a consensus-driven modified Delphi approach. The Key4OI screening set is recommended for regular screening of daily functioning and quality of life [
26].
6. Multidisciplinary Treatment Challenges
There is no cure for OI yet. Current treatment is based on increasing bone mass, prevention of fractures with alignment surgery, fracture management, and rehabilitation. The main treatment goal for children with OI is optimizing mobility, functional independency, and participation in society. The high variability in clinical severity of OI makes standard care recommendations less appropriate. Individually tailored care should therefore be the standard for OI patients. Children with OI as well as their parents often develop a fear of fractures. Health care professionals not used to treating OI patients have this fear as well. This may keep the patient from reaching their full potential in functioning. Therefore, caregivers should be educated how to handle a child with OI from birth [
29]. Overprotection by both patients, their family members, and local healthcare providers may lead to a vicious cycle of fracture, immobilization, deconditioning, reduced skeletal strength and re-fracture. This needs to be addressed in a tailor-made rehabilitation program, including a psychological approach [
30,
31]. All treatment modalities should focus on optimal functioning of the child and family. A team with support of social workers and psychologists might be indicated.
7. Conclusions and Future Perspectives
Next to providing fracture management and prevention in patients with OI, multidisciplinary care should focus on functioning and psychosocial well-being. Despite all research and advances, the current management of fractures in OI remains a combination of surgery and medical treatment and requires a tailor-made approach from a multidisciplinary team of OI experts from different specialties.
Author Contributions
Conceptualization, W.N. and R.S.; original draft preparation, W.N.; writing—review and editing, M.V., C.v.B., H.W., R.S. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Botor, M.; Fus-Kujawa, A.; Uroczynska, M. Osteogenesis Imperfecta: Current and Prospective Therapies. Biomolecules 2021, 11, 1493. [Google Scholar] [CrossRef] [PubMed]
- Van Dijk, F.S.; Sillence, D.O. Osteogenesis imperfecta: Clinical diagnosis, nomenclature and severity assessment. Am. J. Med. Genet. A 2014, 164A, 1470–1481. [Google Scholar] [CrossRef] [Green Version]
- Forlino, A.; Marini, J.C. Osteogenesis imperfecta. Lancet 2016, 387, 1657–1671. [Google Scholar] [CrossRef]
- Kivirikko, K.I. Collagens and their abnormalities in a wide spectrum of diseases. Annu. Med. 1993, 25, 113–126. [Google Scholar] [CrossRef] [PubMed]
- Byers, P.H.; Steiner, R.D. Osteogenesis imperfecta. Annu. Rev. Med. 1992, 43, 269–282. [Google Scholar] [CrossRef]
- Prockop, D.J. Mutations that alter the primary structure of type I collagen. The perils of a system for generating large structures by the principle of nucleated growth. J. Biol. Chem. 1990, 265, 15349–15352. [Google Scholar] [CrossRef]
- Gao, H.; Ji, B.; Jager, I.L.; Arzt, E.; Fratzl, P. Materials become insensitive to flaws at nanoscale: Lessons from nature. Proc. Natl. Acad. Sci. USA 2003, 100, 5597–5600. [Google Scholar] [CrossRef] [Green Version]
- Jäger, I.; Fratzl, P. Mineralized collagen fibrils: A mechanical model with a staggered arrangement of mineral particles. Biophys. J. 2000, 79, 1737–1746. [Google Scholar] [CrossRef] [Green Version]
- Nijhuis, W.H.; Eastwood, D.M.; Allgrove, J.; Hvid, I.; Weinans, H.H.; Bank, R.A.; Sakkers, R.J. Current concepts in osteogenesis imperfecta: Bone structure, biomechanics and medical management. J. Child Orthop. 2019, 1, 1–11. [Google Scholar] [CrossRef]
- Jones, S.J.; Glorieux, F.H.; Travers, R.; Boyde, A. The microscopic structure of bone in normal children and patients with osteogenesis imperfecta: A survey using backscattered electron imaging. Calcif. Tissue Int. 1999, 64, 8–17. [Google Scholar] [CrossRef]
- Yeni, Y.N.; Brown, C.U.; Wang, Z.; Norman, T.L. The influence of bone morphology on fracture toughness of the human femur and tibia. Bone 1997, 21, 453–459. [Google Scholar] [CrossRef]
- Nishiyama, K.K.; Boyd, S.K. In vivo assessment of trabecular and cortical bone microstructure. Clin. Calcium 2011, 21, 1011–1019. [Google Scholar] [PubMed]
- Kocijan, R.; Muschitz, C.; Haschka, J. Bone structure assessed by HR-pQCT, TBS and DXL in adult patients with different types of osteogenesis imperfecta. Osteoporos. Int. 2015, 26, 2431–2440. [Google Scholar] [CrossRef] [PubMed]
- Shapiro, J.R.; McCarthy, E.F.; Rossiter, K. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta. Calcif. Tissue Int. 2003, 72, 103–112. [Google Scholar] [CrossRef] [PubMed]
- Rauch, F.; Travers, R.; Plotkin, H.; Glorieux, F.H. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J. Clin. Investig. 2002, 110, 1293–1299. [Google Scholar] [CrossRef] [PubMed]
- Boutroy, S.; Hans, D.; Sornay-Rendu, E. Trabecular bone score improves fracture risk prediction in non-osteoporotic women: The OFELY study. Osteoporos. Int. 2013, 24, 77–85. [Google Scholar] [CrossRef] [PubMed]
- Winzenberg, T.M.; Powell, S.; Shaw, K.A.; Jones, G. Vitamin D supplementation for improving bone mineral density in children. Cochrane Database Syst. Rev. 2010, 10, e23475. [Google Scholar] [CrossRef]
- Wilsford, L.D.; Sullivan, E.; Mazur, L.J. Risk factors for vitamin D deficiency in children with osteogenesis imperfecta. J. Pediatr. Orthop. 2013, 33, 575–579. [Google Scholar] [CrossRef] [PubMed]
- Sakkers, R.; Kok, D.; Engelbert, R.; van Dongen, A.; Jansen, M.; Pruijs, H.; Verbout, A.; Schweitzer, D.; Uiterwaal, C. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: A 2-year randomised placebo-controlled study. Lancet 2004, 363, 1427–1431. [Google Scholar] [CrossRef]
- Scheres, L.J.J.; van Dijk, F.S.; Harsevoort, A.J.; van Dijk, A.T.H.; Dommisse, A.M.; Janus, G.J.M.; Franken, A.A.M. Adults with osteogenesis imperfecta: Clinical characteristics of 151 patients with a focus on bisphosphonate use and bone density measurements. Bone Rep. 2018, 8, 168–172. [Google Scholar] [CrossRef]
- Chiang, C.Y.; Zebaze, R.M.; Ghasem-Zadeh, A.; Iuliano-Burns, S.; Hardidge, A.; Seeman, E. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone 2013, 52, 360–365. [Google Scholar] [CrossRef] [PubMed]
- Götherström, C.; David, A.L.; Walther-Jallow, L.; Åström, E.; Westgren, M. Mesenchymal Stem Cell Therapy for Osteogenesis Imperfecta. Clin. Obstet. Gynecol. 2021, 64, 898–903. [Google Scholar] [CrossRef]
- Glorieux, F.H.; Devogelaer, J.P.; Durigova, M. BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: Results of a randomized phase 2a trial. J. Bone Miner. Res. 2017, 32, 1496–1504. [Google Scholar] [CrossRef] [PubMed]
- Brotto, M.; Bonewald, L. Bone and muscle: Interactions beyond mechanical. Bone 2015, 80, 109–114. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Veilleux, L.N.; Rauch, F. Muscle-bone interactions in pediatric bone diseases. Curr. Osteoporos. Rep. 2017, 15, .425–432. [Google Scholar] [CrossRef]
- Nijhuis, W.; Franken, A.; Ayers, K.; Damas, C.; Folkestad, L.; Forlino, A.; Fraschini, P.; Hill, C.; Janus, G.; Kruse, R.; et al. A standard set of outcome measures for the comprehensive assessment of osteogenesis imperfecta. Orphanet. J. Rare Dis. 2021, 2021, 16140. [Google Scholar] [CrossRef]
- Azzam, K.A.; Rush, E.T.; Burke, B.R.; Nabower, A.M.; Esposito, P.W. Mid-term Results of Femoral and Tibial Osteotomies and Fassier-Duval Nailing in Children With Osteogenesis Imperfecta. J. Pediatr. Orthop. 2018, 38, 331–336. [Google Scholar] [CrossRef]
- Sakkers, R.J.; Montpetit, K.; Tsimicalis, A.; Wirth, T.; Verhoef, M.; Hamdy, R.; Ouellet, J.A.; Castelein, R.M.; Damas, C.; Janus, G.J.; et al. A roadmap to surgery in osteogenesis imperfecta: Results of an international collaboration of patient organizations and interdisciplinary care teams. Acta Orthop. 2021, 92, 608–614. [Google Scholar] [CrossRef]
- Mueller, B.; Engelbert, R.; Baratta-Ziska, F.; Bartels, B.; Blanc, N.; Brizola, E.; Fraschini, P.; Hill, C.; Marr, C.; Mills, L.; et al. Consensus statement on physical rehabilitation in children and adolescents with osteogenesis imperfecta. Orphanet. J. Rare Dis. 2018, 13, 158. [Google Scholar] [CrossRef] [Green Version]
- Veilleux, L.N.; Pouliot-Laforte, A.; Lemay, M.; Cheung, M.S.; Glorieux, F.H.; Rauch, F. The functional muscle-bone unit in patients with osteogenesis imperfecta type I. Bone 2015, 79, 52–57. [Google Scholar] [CrossRef]
- Tsimicalis, A.; Denis-Larocque, G.; Michalovic, A.; Lepage, C.; Williams, K.; Yao, T.R.; Palomo, T.; Dahan-Oliel, N.; Le May, S.; Rauch, F. The psychosocial experience of individuals living with osteogenesis imperfecta: A mixed-methods systematic review. Qual. Life Res. 2016, 25, 1877–1896. [Google Scholar] [CrossRef] [PubMed]
| Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).